Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-142159

Published: 2020

Journal Articles

Β-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance

Sutapa Sinha, PhD, Charla R Secreto, Justin C. Boysen, Steven L. Warner, PhD, David J. Bearss, PhD, Asish K Ghosh, PhD, Neil E. Kay, MD

Blood (2019) 134 (Supplement_1): 1739.

https://doi.org/10.1182/blood-2019-121772

Published: 2019

Journal Articles

Enhanced Expression of Beta-Catenin and Axl Receptor Tyrosine Kinase (RTK) in Chronic Lymphocytic Leukemia (CLL) B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Leukemic Cell Drug Resistance

Sutapa Sinha, PhD, Charla R Secreto, Justin C. Boysen, Steven L. Warner, PhD, David J. Bearss, PhD, Asish K Ghosh, PhD, Neil E. Kay, MD

Blood (2018) 132 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2018-99-110981

Published: 2018

Journal Articles

The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma

Ethika Tyagi, PhD, Clifford Whatcott, PhD, Jason M Foulks, PhD, Adam Siddiqui-Jain, PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2018) 132 (Supplement 1): 3269.

https://doi.org/10.1182/blood-2018-99-120047

Published: 2018

Journal Articles

The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models

Dipmoy Nath, PhD, Avik Dutta, MSc, Yue Yang, BS, Clifford Whatcott, PhD, Steven L. Warner, PhD, Golam Mohi, PhD

Blood (2018) 132 (Supplement 1): 54.

https://doi.org/10.1182/blood-2018-99-119421

Published: 2018

Journal Articles

The CDK9 Inhibitor, Alvocidib, Potentiates the Non-Clinical Activity of Azacytidine or Decitabine in an MCL-1-Dependent Fashion, Supporting Clinical Exploration of a Decitabine and Alvocidib Combination

Wontak Kim, Clifford Whatcott, PhD, Adam Siddiqui-Jain, PhD, Stephen Anthony, DO, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2018) 132 (Supplement 1): 4355.

https://doi.org/10.1182/blood-2018-99-119793

Published: 2018

Journal Articles

Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies

Reona Sakemura, MD PhD, Nan Yang, MD, Michelle J. Cox, Sutapa Sinha, PhD, Mehrdad Hefazi, MD, Michael J. Hansen, Kendall J. Schick, Cynthia L. Forsman, PhD, Justin C. Boysen, Renee C Tschumper, Elizabeth Juarez Diaz, BS, Lars Mouritsen, Jason M Foulks, PhD, Steven L. Warner, PhD, Sameer A. Parikh, MD, Wei Ding, MD PhD, Neil E. Kay, MD, Saad S. Kenderian, MD

Blood (2018) 132 (Supplement 1): 728.

https://doi.org/10.1182/blood-2018-99-112209

Published: 2018

Journal Articles

TP-0903, a Novel Axl Inhibitor with Activity in Drug Resistant FLT3-ITD+ AML through a Mechanism That Includes FLT3 Inhibition

Jae Yoon Jeon, PharmD, Il-Kyoo Park, PhD, Daelynn R Buelow, PhD, Clifford Whatcott, PhD, Steven L. Warner, PhD, William Blum, MD, Sharyn Baker, PharmD

Blood (2017) 130 (Supplement 1): 2522.

https://doi.org/10.1182/blood.V130.Suppl_1.2522.2522

Published: 2017

Journal Articles

TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency

Peter Peterson, PhD, W K, Clifford Whatcott, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MD PhD, Mark Kieran, MD PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2017) 130 (Supplement 1): 937.

https://doi.org/10.1182/blood.V130.Suppl_1.937.937

Published: 2017

Journal Articles

Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia

Clifford J. Whatcott, PhD, James M Bogenberger, PhD, Wontak Kim, Hillary Haws, Nanna Hansen, M.S., Devora Delman, B.S., Lisa Sproat, MD MSW, Jeanne Palmer, MD, Ruben A. Mesa, MD, Peter Peterson, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MD PhD, David J. Bearss, PhD, Steven L. Warner, PhD, Raoul Tibes, MD PhD

Blood (2016) 128 (22): 1652.

https://doi.org/10.1182/blood.V128.22.1652.1652

Published: 2016

Journal Articles

Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase

Sutapa Sinha, PhD, Justin C Boysen, Kari G. Chaffee, MS, Brian F Kabat, Susan L. Slager, PhD, Sameer A. Parikh, MD, Charla R Secreto, Tait D. Shanafelt, MD, Jose F. Leis, MD PhD, Steven L. Warner, PhD, David J. Bearss, PhD, Asish K Ghosh, PhD, Neil E. Kay, MD

Blood (2016) 128 (22): 2020.

https://doi.org/10.1182/blood.V128.22.2020.2020

Published: 2016

Journal Articles

The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease

Peter Peterson, PhD, Wontak Kim, Hillary Haws, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2016) 128 (22): 263.

https://doi.org/10.1182/blood.V128.22.263.263

Published: 2016

Journal Articles

Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion

Wontak Kim, Katherine K. Soh, Jeremiah J. Bearss, Ye Sol Lee, Peter Peterson, PhD, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MDPhD, James M Bogenberger, PhD, Raoul Tibes, MD PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 1343.

https://doi.org/10.1182/blood.V126.23.1343.1343

Published: 2015

Journal Articles

Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML

Wontak Kim, Brigham L. Bahr, Katherine K. Soh, Jeremiah J. Bearss, Ye Sol Lee, Peter Peterson, PhD, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MDPhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 3799.

https://doi.org/10.1182/blood.V126.23.3799.3799

Published: 2015

Journal Articles

Inhibition of Axl Kinase Reverses the Mesenchymal Phenotype in Leukemic Cells through the Disruption of Retinoic Acid Signaling

Katherine K. Soh, Brigham L. Bahr, Jeremiah J. Bearss, Wontak Kim, Peter Peterson, PhD, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 3253.

https://doi.org/10.1182/blood.V126.23.3253.3253

Published: 2015

Journal Articles

ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease

Peter Peterson, PhD, Katherine K. Soh, Ye Sol Lee, Wontak Kim, Clifford J. Whatcott, PhD, Adam Siddiqui-Jain, PhD, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2015) 126 (23): 273.

https://doi.org/10.1182/blood.V126.23.273.273

Published: 2015

Journal Articles

Axl Regulates Fibroblast Growth Factor Receptor Signaling in B-Cell Chronic Lymphocytic Leukemia: Dual Targeting in CLL Therapy

Sutapa Sinha, PhD, Justin Boysen, Charla Secreto, Steven L. Warner, PhD, Neil E. Kay, MD, Asish K Ghosh, PhD

Blood (2014) 124 (21): 831.

https://doi.org/10.1182/blood.V124.21.831.831

Published: 2014

Journal Articles

Targeted Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for Apoptosis: Synergistic/Additive Effects in Combination with Bruton Tyrosine Kinase Inhibitors

Sutapa Sinha, PhD, Justin Boysen, Michael Nelson, Charla Secreto, Steven L. Warner, PhD, David J. Bearss, PhD, Connie Lesnick, M.Sc, Tait D. Shanafelt, MD, Neil E. Kay, MD, Asish K Ghosh, PhD

Blood (2014) 124 (21): 1946.

https://doi.org/10.1182/blood.V124.21.1946.1946

Published: 2014

Journal Articles

The Receptor Tyrosine Kinase Axl Is Required for Resistance to FLT3-Targeted Therapy in Acute Myeloid Leukemia

Il-Kyoo Park, PhD, Bethany Mundy-Bosse, PhD, Steven L. Warner, PhD, David J. Bearss, PhD, Guido Marcucci, MD, Michael A. Caligiuri, MD

Blood (2014) 124 (21): 2350.

https://doi.org/10.1182/blood.V124.21.2350.2350

Published: 2014

Journal Articles

Novel Series of ALK2 Inhibitors That Alter Hepcidin Expression As Potential Therapeutics for Anemia of Chronic Disease

Wontak Kim, Kyle S. Maughan, Katherine K. Soh, Jeremiah J. Bearss, Brigham L. Bahr, David J. Bearss, PhD, Steven L. Warner, PhD

Blood (2014) 124 (21): 212.

https://doi.org/10.1182/blood.V124.21.212.212

Published: 2014

NARROW

Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models

Β-Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance

Enhanced Expression of Beta-Catenin and Axl Receptor Tyrosine Kinase (RTK) in Chronic Lymphocytic Leukemia (CLL) B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Leukemic Cell Drug Resistance

The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma

The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models

The CDK9 Inhibitor, Alvocidib, Potentiates the Non-Clinical Activity of Azacytidine or Decitabine in an MCL-1-Dependent Fashion, Supporting Clinical Exploration of a Decitabine and Alvocidib Combination

Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies

TP-0903, a Novel Axl Inhibitor with Activity in Drug Resistant FLT3-ITD+ AML through a Mechanism That Includes FLT3 Inhibition

TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency

Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia

Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase

The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease

Alvocidib Potentiates the Activity of Azacytidine in an MCL-1-Dependent Fashion

Alvocidib Potentiates the Activity of Cytarabine and Mitoxantrone through the Targeting of MCL-1 When Administered in a Time Sequential Regimen in AML

Inhibition of Axl Kinase Reverses the Mesenchymal Phenotype in Leukemic Cells through the Disruption of Retinoic Acid Signaling

ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease

Axl Regulates Fibroblast Growth Factor Receptor Signaling in B-Cell Chronic Lymphocytic Leukemia: Dual Targeting in CLL Therapy

Targeted Inhibition of Axl Primes Chronic Lymphocytic Leukemia B-Cells for Apoptosis: Synergistic/Additive Effects in Combination with Bruton Tyrosine Kinase Inhibitors

The Receptor Tyrosine Kinase Axl Is Required for Resistance to FLT3-Targeted Therapy in Acute Myeloid Leukemia

Novel Series of ALK2 Inhibitors That Alter Hepcidin Expression As Potential Therapeutics for Anemia of Chronic Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only